(Q40068596)

17 September 2017

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models (English)

1 reference

17 September 2017

1 reference

8

Patrick Hwu

1 reference

17 September 2017

4

Sattva S Neelapu

1 reference

17 September 2017

Kuichun Zhu

1

1 reference

17 September 2017

Hong Qin

2

1 reference

17 September 2017

Soung-Chul Cha

3

1 reference

17 September 2017

Willem Overwijk

5

1 reference

17 September 2017

Gregory A Lizee

6

1 reference

17 September 2017

James L Abbruzzese

7

1 reference

17 September 2017

Laszlo Radvanyi

9

1 reference

17 September 2017

Larry W Kwak

10

1 reference

17 September 2017

David Z Chang

11

1 reference

17 September 2017

language of work or name

English

0 references

publication date

14 September 2007

1 reference

17 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

17 September 2017

25

1 reference

17 September 2017

46

1 reference

17 September 2017

7955-7961

1 reference

Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Survivin' cell-separation anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Cancer gene therapy using a survivin mutant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Survivin expression is a prognostic marker in pancreatic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A role for survivin in radioresistance of pancreatic cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.050

10.1016/J.VACCINE.2007.08.050

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference